Until vaccine has passed all preclinical and clinical trials as well as FDA approval, the best approach to containing the pathogenicity and infectivity of COVID-19 will involve testing. The Safra center at Harvard advised to have up to 5 million tests being conducted within a day. Testing will not only slow down the spread, but also allow reopening of businesses and schools. So far, many testing methods involve viral RNAs or antigens. For detecting viral RNAs, most involve using RT-qPCR conjugated with Next Generation Sequencing to identify specific unique viral sequences. Recently, SHERLOCK detection technique utilizing CRISPR-Cas13 was tested in Broad Institute using a catalytically dead Cas13 to bind to specific viral sequences. On the other hand, detection of viral antigens involve either using ELISA with selected antibodies against viral antigens or using lateral flow assay.